Mulpleta Tablets 3mg drug use-results survey

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080223377

Enrollment

1000

Registered

2016-11-15

Start date

2016-10-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thrombocytopenia associated with chronic liver disease

Interventions

investigational material(s) Generic name etc : Mulpleta Tablets 3mg (lusutrombopag) INN of investigational material : Lusutrombopag Therapeutic category code : 339 Other agents relating to blood and b

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic liver disease who have thrombocytopenia and are scheduled for an elective invasive procedure

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
safety efficacy Safety, efficacy	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026